Table 1 Summary of studies from systematic review of DOAC vs. LMWH for thromboprophylaxis after cancer-related surgery
Study | Publication Type | Design | Median age(years)a | Malea% | Malignancy Type | Study Sizea | Intervention | Outcomes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
DOAC | LMWH | Endpoint (time) | DOAC | LMWH | |||||||
Guntupalli 2020 [21] | Full-Text | RCT | 58/58.5 | 0 | Gynecologic malignancy | 204/196 | Apixaban | Enoxaparin | VTE (90Â days) MB(30Â days) CRNMB(30Â days) Readmission (30Â days) | 1%(2/204) 0.5%(1/204) 5.9%(12/204) 2.9%(6/204) | 1.5%(3/196) 0.5%(1/196) 9.7%(19/196) 2.6%(5/196) |
Oliveira 2022 [22] | Full-Text | RCT | 54/56 | 0 | Gynecologic malignancy | 114/114 | Rivaroxaban | Enoxaparin | VTE(30Â days) MB(30Â days) CRNMB(30Â days) | 3.5%(4/114) 0%(0/114) 0%(0/114) | 4.4%(5/114) 0%(0/114) 2.6%(3/114) |
Zhao 2023 [32] | Full-Text | RCT | 61.2/61.7 | 53.5/47.3b | Lung cancer | 200/203 | Rivaroxaban | nadroparin | VTE(30Â days) MB(30Â days) CRNMB(30Â days) | 12.5%(25/200) 9.7%(19/196) 2.5%(5/196) | 17.7%(36/203) 6.5%(13/201) 0.5%(1/201) |
Nagy 2018 [33] | Abstract | Observational study | NR | 0 | Gynecologic malignancy | 147/451 | Rivaroxaban | LMWH | VTE (90Â days) bleeding complications(NR) | 0.7%(1/147) 2%( 3/147) | 2.4%(11/451) 0.7%( 3/451) |
Spénard 2023 [37] | Full-Text | Observational study | 60/63 | 0 | Gynecologic malignancy | 112/144 | Apixaban | Enoxaparin | VTE(30 days) MB(30 days) Readmission (30 days) | 3%(3/112) 0%(0/112) 6%(7/112) | 4%(6/144) 0%(0/144) 5%(7/144) |
Swaroop 2021 [38] | Abstract | Observational study | NR | 0 | Gynecologic malignancy | 82/233 | Rivaroxaban | LMWH | VTE (30Â days) VTE (90Â days) MB (30Â days) | 1.2%(1/82) 2.4%(2/82) 3.7%(3/82) | 1.7%(4/233) 4.3%(10/233) 0.4%(1/233) |
Rashid 2018 [35] | Full-Text | Observational study | NR | 59 | Pancreatic adenocarcinoma | 87/12 | dabigatran | Enoxaparin | MB (90Â days) Minor bleeding(90Â days) | 4.5%(4/87) 2.3%(2/87) | 0%(0/12) 0%(0/12) |
Rich 2023 [36] | Full-Text | Observational study | 69/69 | 82/76 | Bladder cancer | 124/250 | Apixaban | Enoxaparin | VTE (30Â days) MB (30Â days) Readmission (30Â days) Mortality (30Â days) | 1.6%(2/124) 0.8%(1/124) 20%(25/124) 0.8%(1/124) | 3.2%(8/250) 0.4%(1/250) 19%(48/250) 1.6%(4/250) |
Westerman 2022 [39] | Full-Text | Observational study | 66/66 | 84/79 | Urological malignancy | 154/161 | Apixaban | Enoxaparin | VTE(30Â days) MB(30Â days) CRNMB(30Â days) | 0%(0/154) 0%(0/154) 3.9%(6/154) | 1.7%(3/161) 1.2%(2/161) 4.3%(7/161) |
Ortiz 2021 [34] | Full-Text | Observational study | 65/68 | 69/70 | Bladder cancer | 29/37 | Rivaroxaban (83%), Apixaban(14%) and Dabigatran(3%) | Enoxaparin | VTE(30Â days) VTE(90Â days) CRNMB(30Â days) Readmission (30Â days) | 0%(0/29) 3.4%(1/29) 3.4%(1/29) | 0%(0/37) 8.1%(3/37) 0%(0/37) |